Advanced Search

UACC-1598 (ATCC® CRL-3128™)

Organism: Homo sapiens, human  /  Tissue: ovary  /  Disease: cystadenocarcinoma, Grade IV

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue ovary
Product Format frozen
Morphology epithelial-like
Culture Properties adherent
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.
Disease cystadenocarcinoma, Grade IV
Age 78 years
Gender female
Applications
Pathology confirmed that the specimen was a grade IV poorly differentiated papillary serous cystadenocarcinoma.
The human ovarian cancer cell line, UACC-1598, was derived from the right ovary of an untreated 78-year-old female.
The UACC-1598 cell line expresses the N-myc oncogene, which is rarely amplified in ovarian cancers.
UACC-1598 cells express low levels of Epidermal Growth Factor Receptor erbB2, and are negative for ras by ELISA assay.
A high copy number amplification of eukaryotic translation initiation factor 5A2 (eIF-5A2) oncogene was detected in this region.
Storage Conditions liquid nitrogen vapor phase
Derivation
The human ovarian cancer cell line, UACC-1598, was derived from the right ovary of an untreated 78-year-old female. Pathology confirmed that the specimen was a grade IV poorly differentiated papillary serous cystadenocarcinoma.
The UACC-1598 cell line contains high-level amplification at 3q26 in the form of double minute chromosomes. A high copy number amplification of eukaryotic translation initiation factor 5A2 (eIF-5A2) oncogene was detected in this region. Overexpression the eIF-5A2 oncogene may play an important role in ovarian cancer pathogenesis.
Clinical Data
The human ovarian cancer cell line, UACC-1598, was derived from the right ovary of an untreated 78-year-old female.
female
Receptor Expression
Epidermal Growth Factor Receptor (EGFR), low expression
Oncogene N-myc, positive; eukaryotic translation initiation factor 5A2 (eIF-5A2), positive; c-erbB2, low expression; ras, negative
Genes Expressed
cytokeratin (MAK-6), not expressed,progesterone, not expressed,N-myc, positive; eukaryotic translation initiation factor 5A2 (eIF-5A2), positive; c-erbB2, low expression; ras, negative
Cellular Products
cytokeratin (MAK-6), not expressed
progesterone, not expressed
Comments
The human ovarian cancer cell line, UACC-1598, was derived from the right ovary of an untreated 78-year-old female. Pathology confirmed that the specimen was a grade IV poorly differentiated papillary serous cystadenocarcinoma.
The UACC-1598 cell line expresses the N-myc oncogene, which is rarely amplified in ovarian cancers.
UACC-1598 cells express low levels of Epidermal Growth Factor Receptor erbB2, and are negative for ras by ELISA assay.
The UACC-1598 cell line contains high-level amplification at 3q26 in the form of double minute chromosomes. A high copy number amplification of eukaryotic translation initiation factor 5A2 (eIF-5A2) oncogene was detected in this region. Overexpression the eIF-5A2 oncogene may play an important role in ovarian cancer pathogenesis.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Leibovitz's L-15 Medium, Catalog No. 30-2008. To make the complete growth medium, add the following components to the base medium:
  • fetal bovine serum to a final concentration of 5%
  • 0.01 mg/ml transferrin (final conc.)
  • 0.01 mg/ml insulin (final conc.)
  • 5 µg/mL (55 U/ml) catalase (final conc.)
  • 3.6 µg/mL (0.01 mM) hydrocortisone (final conc.)
  • 70 µg/mL (0.5mM) o-phosphoethanolamine (final conc.)
  • 10 ng/ml human recombinant epidermal growth factor (EGF) (final conc.)
  • 3 ng/ml (0.01 µM) estradiol (final conc.)
  • 0.8 ng/ml (1 pM) Na-L-thyroxine (final conc.)
  • extra 2 mM glutamine

Note: Do not filter complete medium.
Subculturing
Protocol:
Subculture when cells reach 80% to 90% confluence. These cells pile up and slough off the flask surface if they become over-confluent.
Volumes used in this protocol are for 75 cm2 flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with Ca++/Mg++ free Dulbecco's phosphate-buffered saline (D-PBS) or 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
  3. Add 1.0 to 2.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37.0°C to facilitate dispersal.
  4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
  5. Transfer cell suspension to a centrifuge tube and spin at approximately 125 x g for 5 to 10 minutes. Discard supernatant.
  6. Resuspend the cell pellet in fresh growth medium. Add appropriate aliquots of the cell suspension to new culture vessels.
  7. Incubate cultures at 37.0°C in atmospheric air without additional CO2.
Subcultivation ratio: A subcultivation ratio of 1:2 is recommended.
Medium renewal: every 5 to 7 days
Cryopreservation
Freeze medium: complete growth medium supplemented with an additional 10% fetal bovine serum (FBS) and 10% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Temperature: 37.0°C
Atmosphere: air, 100%
Growth Conditions: These cells grow very slowly.
STR Profile
CSF1PO: 10
D13S317: 13
D16S539: 11, 12
D5S818: 13
D7S820: 7, 9
THO1: 7, 9.3
TPOX: 8, 11
vWA: 14
Amelogenin: X
Name of Depositor K Brown
Year of Origin January 1989
References

Heiskanen MA, et al. Detection of gene amplification by genomic hybridization to cDNA microarrays. Cancer Res. 60(4): 799-802, 2000. PubMed: 10706083

Guan XY, et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Research 64 (12): 4197-4200, 2004. PubMed: 15205331

Clement P, et al. Identification and characterization of eukaryotic initiation factor 5A-2. Eur. J. Biochem. 147(21): 4254-4263, 2003. PubMed: 14622290

Clement P, et al. Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J. 273(6): 1102-1114: 2006. PubMed: 16519677

Guan XY, et al. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res. 61(9): 3806-3809, 2001. PubMed: 11325856

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
SDS
SDS
References

Heiskanen MA, et al. Detection of gene amplification by genomic hybridization to cDNA microarrays. Cancer Res. 60(4): 799-802, 2000. PubMed: 10706083

Guan XY, et al. Oncogenic role of eIF-5A2 in the development of ovarian cancer. Cancer Research 64 (12): 4197-4200, 2004. PubMed: 15205331

Clement P, et al. Identification and characterization of eukaryotic initiation factor 5A-2. Eur. J. Biochem. 147(21): 4254-4263, 2003. PubMed: 14622290

Clement P, et al. Differential expression of eIF5A-1 and eIF5A-2 in human cancer cells. FEBS J. 273(6): 1102-1114: 2006. PubMed: 16519677

Guan XY, et al. Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. Cancer Res. 61(9): 3806-3809, 2001. PubMed: 11325856